Ottimo Pharma develops innovative cancer therapies using PD1-VEGFR2 antibodies.
Ottimo Pharma has raised $140.0M in total funding. The most recent round was Series A. The last funding was announced in December 2024.
Ottimo Pharma's investors include Janus Henderson Investors, Samsara BioCapital, OrbiMed, RTW Investments, Decheng Capital.
Ottimo Pharma is headquartered in Sandwich, United Kingdom.
Ottimo Pharma develops innovative cancer therapies using PD1-VEGFR2 antibodies.
Ottimo Pharma is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Ottimo Pharma — Funding & Investors." VCBacked, December 19, 2024, https://www.vcbacked.co/company/ottimo-pharma. Accessed October 22, 2026.
VCBacked. (2024). Ottimo Pharma — Funding & Investors. Retrieved October 22, 2026, from https://www.vcbacked.co/company/ottimo-pharma
{{cite web |title=Ottimo Pharma — Funding & Investors |url=https://www.vcbacked.co/company/ottimo-pharma |website=VCBacked |access-date=October 22, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated